Eledon Pharmaceuticals Files 8-K on Financials
Ticker: ELDN · Form: 8-K · Filed: May 13, 2024 · CIK: 1404281
| Field | Detail |
|---|---|
| Company | Eledon Pharmaceuticals, Inc. (ELDN) |
| Form Type | 8-K |
| Filed Date | May 13, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, corporate-actions
TL;DR
Eledon Pharma dropped an 8-K on May 13th covering financial results and exhibits from May 9th.
AI Summary
Eledon Pharmaceuticals, Inc. filed an 8-K on May 13, 2024, reporting on events from May 9, 2024. The filing pertains to Results of Operations and Financial Condition, as well as Financial Statements and Exhibits. The company, formerly known as Novus Therapeutics, Inc. and Tokai Pharmaceuticals Inc., is incorporated in Delaware and headquartered in Irvine, California.
Why It Matters
This 8-K filing provides an update on Eledon Pharmaceuticals' financial condition and results of operations, which is crucial information for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This filing is a standard 8-K reporting routine financial and operational information, not indicating any immediate or significant new risks.
Key Players & Entities
- Eledon Pharmaceuticals, Inc. (company) — Registrant
- May 09, 2024 (date) — Earliest event reported
- May 13, 2024 (date) — Date of Report
- Novus Therapeutics, Inc. (company) — Former company name
- Tokai Pharmaceuticals Inc (company) — Former company name
- 19800 MacArthur Blvd. Suite 250 (address) — Principal Executive Offices
- Irvine, California (location) — Principal Executive Offices
FAQ
What specific financial results are being reported in this 8-K?
The filing indicates it pertains to 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits', but the specific details of the financial results are not provided in the excerpt.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on May 09, 2024.
What is the company's current principal executive office address?
The company's principal executive offices are located at 19800 MacArthur Blvd. Suite 250, Irvine, California.
What were Eledon Pharmaceuticals' previous names?
Eledon Pharmaceuticals, Inc. was formerly known as Novus Therapeutics, Inc. and Tokai Pharmaceuticals Inc.
What is the Standard Industrial Classification (SIC) code for Eledon Pharmaceuticals?
The SIC code for Eledon Pharmaceuticals is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 522 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2024-05-13 16:30:23
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value ELDN Nasdaq Global Market
Filing Documents
- eldn-20240509.htm (8-K) — 42KB
- eldn-ex99_1.htm (EX-99.1) — 118KB
- img20068692_0.jpg (GRAPHIC) — 11KB
- 0000950170-24-058706.txt ( ) — 322KB
- eldn-20240509.xsd (EX-101.SCH) — 42KB
- eldn-20240509_htm.xml (XML) — 6KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On May 9, 2024, Eledon Pharmaceuticals, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended March 31, 2024. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is furnished to comply with Item 2.02 of Form 8-K, and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release Issued on May 9, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Eledon Pharmaceuticals, Inc. Date: May 13, 2024 By: /s/ David-Alexandre C. Gros, M.D. Name: David-Alexandre C. Gros, M.D. Title: Chief Executive Officer